ALN-ANG3 + Evinacumab for Diabetic Kidney Disease

(ANCHOR-POC Trial)

This trial tests two experimental drugs, ALN-ANG3 and evinacumab, to determine their safety and effectiveness for people with diabetic kidney disease. Researchers aim to learn about any side effects and how the drugs move through the body. Participants with type 2 diabetes and kidney problems affecting daily life might be suitable candidates. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Research has shown that ALN-ANG3 and evinacumab have been generally safe in earlier studies. ALN-ANG3 is still under investigation to further assess its safety and effectiveness. Participants in past studies have not reported major safety issues, but detailed safety information continues to be gathered.

For evinacumab, studies have found it to be generally well-tolerated. Previous research used it to treat high cholesterol, and patients did not experience significant side effects. Notably, the FDA has approved evinacumab for other conditions, indicating a certain level of safety.

Researchers are excited about ALN-ANG3 and evinacumab for diabetic kidney disease because these treatments target underlying issues differently than current options like ACE inhibitors or ARBs, which mainly control blood pressure. ALN-ANG3 works by inhibiting a protein involved in lipid metabolism, potentially addressing the disease's root causes by reducing harmful lipid levels. Evinacumab is an antibody that lowers bad cholesterol by targeting a protein called angiopoietin-like 3, which could provide additional benefits for kidney function. These novel approaches could offer new hope for patients by not just managing symptoms but also slowing the disease's progression.

Research has shown that ALN-ANG3, which targets the protein ANGPTL3, may help manage kidney diseases related to fat issues. Studies have found that blocking ANGPTL3 can benefit conditions like diabetic kidney disease. In this trial, some participants will receive ALN-ANG3 combined with Evinacumab, another promising treatment. Past studies demonstrated that Evinacumab lowers bad cholesterol (LDL) by 45.5%. Lowering cholesterol is important because it can help prevent kidney damage. Together, these drugs offer hope for treating diabetic kidney disease by addressing underlying fat problems.¹³⁴⁵⁶